Azenta, Inc. reported a weaker-than-expected Q2 FY'26 with a net loss driven by a $149 million goodwill impairment. The company lowered its FY'26 revenue guidance to $603-$621 million, with organic revenue expected to decline 2% to grow 1%, down from prior growth estimates of 3%-5%. Adjusted EBITDA margin is now expected to decline or remain flat, and the long-range plan timeline has been extended to 2029. Despite near-term challenges, Azenta remains confident in its long-term strategy and market opportunities.
Implicity received FDA clearance for its next-generation ILR ECG Analyzer, an AI-powered cloud software that reduces false-positive alerts from implantable cardiac monitors by up to 76% while maintaining high sensitivity for true cardiac events. The ...
YieldMax ETFs announced weekly distributions for their Group 1 ETFs, with distribution rates ranging from 26.17% to 60.34% annualized. These ETFs cover sectors like semiconductors, AI & tech, crypto, metals, and covered call strategies. Distributions...
The global ultrasonic aspirator market, valued at $194 million in 2025, is projected to grow at a CAGR of 6.87% to reach $376 million by 2035. Growth is fueled by increased use in neurosurgery, orthopedic, and minimally invasive surgeries, driven by ...
MEXC's RealStocks platform, launched in June 2026, saw SpaceX (SPCX) capture nearly 30% of trading volume and user activity, marking it as the most popular stock among over 7,000 US stocks and ETFs available. AI-related stocks collectively accounted ...
The SCHD ETF currently offers a 3.3% yield and is on track to complete its 15th consecutive year of dividend increases in 2026. This consistent dividend growth highlights SCHD's appeal for income-focused investors seeking reliable payouts. Maintainin...
